Synthesis and structural characterization of a monocarboxylic inhibitor for GRB2 SH2 domain.

Bioorg Med Chem Lett

Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, United States; Department of Chemistry, University of South Florida, Tampa, FL, United States. Electronic address:

Published: November 2021

A monocarboxylic inhibitor was designed and synthesized to disrupt the protein-protein interaction (PPI) between GRB2 and phosphotyrosine-containing proteins. Biochemical characterizations show compound 7 binds with the Src homology 2 (SH2) domain of GRB2 and is more potent than EGFR phosphopeptide 14-mer. X-ray crystallographic studies demonstrate compound 7 occupies the GRB2 binding site for phosphotyrosine-containing sequences and reveal key structural features for GRB2-inhibitor binding. This compound with a -1 formal charge offers a new direction for structural optimization to generate cell-permeable inhibitors for this key protein target of the aberrant Ras-MAPK signaling cascade.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526398PMC
http://dx.doi.org/10.1016/j.bmcl.2021.128354DOI Listing

Publication Analysis

Top Keywords

monocarboxylic inhibitor
8
sh2 domain
8
synthesis structural
4
structural characterization
4
characterization monocarboxylic
4
grb2
4
inhibitor grb2
4
grb2 sh2
4
domain monocarboxylic
4
inhibitor designed
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!